For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Quetiapine Fumarate is an atypical antipsychotic drug used to treat psychiatric disorders such as schizophrenia, bipolar disorder and depression. It may be used alone or in combination with other psychiatric medications. It is taken orally, and is available only by prescription, under the supervision of a medical practitioner.
Scope of the Report:
The Quetiapine Fumarate was developed by AstraZeneca from 1992 to 1996. It was first approved by the FDA in 1997.
The product is invented and first produced in the UK by AstraZeneca. AstraZeneca is also the leader of the Quetiapine Fumarate base drugs.
The Average gross of the industry is over 40%. However, since there are new companies coming into the area, the gross is declining in the last several years.
The worldwide market for Quetiapine Fumarate is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Quetiapine Fumarate in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- AstraZeneca
- Intas
- TAPI
- Accord
- Hexal
- Dr.Reddy's
- Lupin
- Sun Pharmaceutical
- Hunan Dongting Pharm
- SuZhou NO.4 Phamaceutical Factory
- Fuan Pharmaceutical
- Zhejiang Supor Pharmaceuticals
- Zhejiang Huahai Pharmaceutical
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Immediate Release Tablets
- Extended Release Tablets
Market Segment by Applications, can be divided into
- Application I
- Application II
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Quetiapine Fumarate product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Quetiapine Fumarate, with price, sales, revenue and global market share of Quetiapine Fumarate in 2017 and 2018.
Chapter 3, the Quetiapine Fumarate competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Quetiapine Fumarate breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Quetiapine Fumarate market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Quetiapine Fumarate sales channel, distributors, customers, research findings and conclusion, appendix and data source.